|
|
The present state of antineoplaston research
(1)
Burzynski SR
Burzynski Research Institute, Houston, TX 77055, USA.
info@burzynskiclinic.com
Antineoplastons work as molecular switches, which regulate expression of genes
p53 and p21 through demethylation of promoter sequences and acetylation of
histones.
They also inhibit the uptake of growth-critical amino acids, such as 1-glutamine
and 1-leucine in neoplastic cells.
Phase II trials indicate efficacy of antineoplastons in low-grade glioma, brain
stem glioma, high-grade glioma, adenocarcinoma of the colon, and hepatocellular
carcinoma.
The best results were observed in children with low-grade glioma, where 74% of
patients obtained objective response, and in patients with adenocarcinoma of the
colon with liver metastases whose survival rate of more than 5 years is 91%
versus 39% in controls on chemotherapy.
Gene array studies will explain antineoplaston-induced changes in gene
expression.
PMID: 15035876 [PubMed - indexed for MEDLINE]
Source: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=15035876
|
